1회 2회 분복 투여하는 Moclobemide의 효과와 안전성 : 주요우울장애 환자에서 개방 시험

윤진상,이형영,국승희,최영,Yoon, Jin-Sang,Lee, Hyung-Young,Kook, Seung-Hee,Choi, Young 대한생물정신의학회 1996 생물정신의학 Vol.3 No.1

본 연구는 한국인의 우울증 환자에서 moclobemide가 효과적이며 안전하게 사용될 수 있음을 입증하였으며, 투약 방법으로 초기 권장량인 1일 300mg을 2회 분복시키는 방법이 추천될 수 있음을 확인하였다. This was an open trial to evaluate the efficacy and safety of moclobemide twice daily for treatment of Korean patients with major depressive disorder(DSM-III-R). The duration of the trial was 6 weeks with the initial dose of moclobemide being fixed lor the first two weeks at 300mg/day(150mg twice daily, each token after morning and evening meals). Thereafter, when necessary, the dose was allowed to increase to 600mg/day or decrease to 150mg/day according to the seventy of the depression and/or the tolerability of the drug. Hypnotics and/or sedatives from a benzodiazepine group could be concomitantly administered at usual dosage. Patients were assessed at baseline and at days 14, 28 and 42. Efficacy was primarily judged on the Hamilton Rating Scale for Depression(HAM-D) and Beck Depression Inventory(BDI). Patients had to score at least 17 respectively an both scales to enter the trial. Secondary efficacy parameters included Clinical Global Impression(CGI) for severity of illness and improvement. Safety and tolerability were judged on reported adverse events, vital signs and laboratory parameters. In addition, there was a series of questions and assessments for the psychiatrists and patients to complete at the end of the trial Twenty nine patients completing trial were included in the analysis of efficacy : of thirty one patients participating in the safety and tolerability analysis, those who withdraw voluntarily without particular reasons or violated the treatment schedule were not included. The efficacies as determined by HAM-D, BDI or CGI were found to be significant compared to baseline. The number of responders defined as patients with a total score of 10 or less or with a total score of 50% or less of the baseline score on HAM-D and BDI were 17(59%) and 18(62%) respectively. Regarding safety and tolerability, nine patients(29%) reported mild adverse events probably related to moclobemide : of these one patient dropped out because of poor tolerability : however, there were no appreciable changes in blood pressure, pulse rate, body weight or laboratory parameters for all patients over the trial period. Furthermore, the physicians' and patients' opinions at final evaluation showed that moclabemide has a good antidepressant effect as well as a favorable tolerability. In conclusion, a twice-daily dosage schedule with maclobemide is recommendable for the treatment of Korean patients with major depressive disorder since its efficacy and safety were demonstrated in this study.

유한요소 해석을 통한 전자담배의 안정성 개선에 관한 연구

윤진상 ( Jin-sang Yoon ),이석호 ( Seok-ho Rhi ),김기범 ( Kibum Kim ) 충북대학교 산업과학기술연구소 2019 산업과학기술연구 논문집 Vol.33 No.1

Unlike conventional tobacco, a electronic cigarette contains fewer harmful substances and has advantage of helping quit smoking. As a result, the interest in electronic cigarette is growing, and the worldwide supply is growing rapidly. However, while these advantages exist, many accidents such as explosions and fires have also occurred due to mechanical defects or user’s carelessness. The primary cause of these accidents is the overheating, which causes explosion of batteries or cartomizer. While these problems have been presented, the use of electronic cigarette continues to increase, but research to solve the problem is insufficient. Thus, in this paper, simulation study was carried out to prevent overheating by modifying the shape and material of the carotamizer's component. The study was conducted through finite element analysis using Ansys Fluent with various situations and conditions. The total case studies presented in this paper are 48 cases, and effective alternatives were proposed to prevent explosion or fire caused by overheating.

항우울제의 임상사용을 위한 실제적 지침 : 주요 우울증을 중심으로

윤진상,Yoon, Jin-Sang 대한생물정신의학회 1994 생물정신의학 Vol.1 No.1

Several different classes of antidepressants(ADs) with newer drugs becoming available have been used for the phamacological management of a broad spectrum of mental disorders, among which depressive disorder is most commonly indicated. Successful clinical use of ADs requires a complete understanding of the psychopharmacological properties of ADs and on accurate knowledge of patients, characteristics based on clinical experience and theoretical framework. This paper aims at providing some practical information on the clinical use of ADs to assist clinicians in treating patients with major depression. The author describes (1) different classes of ADs and their presumed mechanisms of action, (2) clinical characteristics of ADs focusing on side-effect profiles, (3) some issues arising during the treatment course such as : a) pretreatment tasks, b) choice of ADs, c) therapeutic drug dose and monitoring of drug concentration, d) three stages of treatment and e) strategies in refractory depression and (4) ADs in special patient groups.

주정중독에 동반된 우울증의 치료에서 Paroxetine과 Amitriptyline의 이중맹 비교 : 치료초기 2주 동안의 행동학적 부작용

윤진상,윤보현,최태석,김용범,이형영,Yoon, Jin-Sang,Yoon, Bo-Hyun,Choi, Tae-Seok,Kim, Yong-Bum,Lee, Hyung-Yung 대한생물정신의학회 1996 생물정신의학 Vol.3 No.2

본 연구는 주정중독에 동반된 우울증 환자의 치료에서 적어도 행동학적 부작용의 관점에서는 PAR이 AMI보다 우수함을 증명하였다. 이러한 PAR의 행동학적 효과의 우수성은 환자의 삶의 질을 향상시키고 결국 치료결과를 높이는데 관여하리라고 생각된다. Objective : It has been proposed that cognition and related aspects of mental functioning are decreased in depression as well as in alcoholism. The objective of the study was to compare behavioral side effects of paroxetine and amitriptyline in depressed patients accompanied by alcoholism. The focused comparisons were drug effects concerning psychomotor performance, cognitive function, sleep and daytime sleepiness during the first 2 weeks of treatment. Methods : After an alcohol detoxification period(3 weeks) and a washout period(1 week), a total of 20 male inpatients with alcohol use disorder (DSM-IV), who also had a major depressive episode(DSM-IV), were treated double-blind with paroxetine 20mg/day(n=10) or amitriptyline 25mg/day(n=10) for 2 weeks. All patients were required to have a scare of at least 18 respectively on bath the Hamilton Rating Scale far Depression(HAM-D) and Beck Depression Inventory(BDI) at pre-drug baseline. Patients randomized to paroxetine received active medication in the morning and placebo in the evening whereas those randomized to amitriptyline received active medication in the evening and placebo in the morning. All patients performed the various tasks in a test battery at baseline and at days 3, 7 and 14. The test battery included : critical flicker fusion threshold for sensory information processing capacity : choice reaction time for gross psychomotor performance : tracking accuracy and latency of response to peripheral stimulus as a measure of line sensorimotor co-ordination and divided attention : digit symbol substitution as a measure of sustained attention and concentration. To rate perceived sleep and daytime sleepiness, 10cm line Visual analogue scales were employed at baseline and at days 3, 7 and 14. The subjective rating scales were adapted far this study from Leeds sleep Evaluation Questionnaire and Epworth Sleepiness Scale. In addition a comprehensive side effect assessment, using the UKU side effect rating scale, was carried out at baseline and at days 7 and 14. The efficacy of treatment was evaluated using HAM-D, BDI and clinical global impression far severity and improvement at days 7 and 14. Results : The pattern of results indicated thai paroxetine improved performance an mast of the lest variables and also improved sleep with no effect on daytime sleepiness aver the study period. In contrast, amitriptyline produced disruption of performance on same tests and improved sleep with increased daytime sleepiness in particular at day 3. On the UKU side effect rating scale, mare side effects were registered an amitriptyline. The therapeutic efficacy was observed in favor of paroxetine early in day 7. Conclusion : These results demonstrated thai paroxetine in much better than amitriptyline for the treatment of depressed patients accompained by alcoholism at least in terms of behavioral safety and tolerability, furthermore the results may assist in explaining the therapeutic outcome of paroxetine. For example, and earlier onset of antidepressant action of paroxetine may be caused by early improved cognitive function or by contributing to good compliance with treatment.

강한 한국 성인에서 ALDH2 유전형에 따라 Metadoxine(Alcotel ??)이 알코올의 약동학 및 약역학에 미치는 영향

윤진상(Jin-Sang Yoon),윤보현(Bo-Hyun Yoon),이용복(Yong-Bok Lee),신일선(Il-Seon Shin),정재성(Jae-Sung Jung),정원태Won-Tae Jung),시영화(Young-Hwa She) 한국중독정신의학회 2000 중독정신의학 Vol.4 No.1

Objectives:Metadoxine is known to have accelerated the metabolism of alcohol in previous studies with Caucasian subjects. The purpose of this study was to evaluate the effects of metadoxine on alcohol pharmacokinetics and pharmacodynamics in normal Korean adults according to the low-Km aldehyde dehydrogenase (ALDH2) genotypes. Methods:Twenty healthy male volunteers (half with active ALDH2*1/*1:active group, the other with inactive ALDH2*1/*2:inactive group) were selected by genotyping. In a double-blind, counterbalanced design, each subject ingested 0.5 g of alcohol per kg of body weight with pretreatment of metadoxine or placebo on 2 separate occasions. Blood alcohol concentration by breathanalyzer (BrAC), vital signs, negative physiological responses and performance function using a battery of tests (critical flicker fusion threshold:CFFT, choice reaction time:CRT, compensatory tracking task:CTT and digit-symbol substitution:DSS) were measured at baseline and repeatedly over a 3-hour period after intake of alcohol. Results:Among the pharmacokinetic parameters, Vmax and Km were significantly increased with pretreatment of metadoxine in both the active and inactive ALDH2 groups, but the ratio of Vmax/Km was decreased. In terms of pharmacodynamics, the pretreatment of metadoxine produced a significant improvement of performance such as CFFT and DSS in the active ALDH2 group, but did not in the inactive ALDH2 group. Conclusions:It may be concluded that metadoxine has little effect on alcohol metabolism in both groups with respect to pharmacokinetics on the basis of BrAC. The pharmacodynamic results, however, indicated that metadoxine might be partially effective in counteracting the impairing effects of alcohol on the performance in the active ALDH2 group.

전자석 시스템 기반의 입각기 제어용 족관절 보조기 개발

윤진상(Yoon Jin Sang),안승근(Ahn Seung Guen),배태수(Bae Tae Soo) 대한전기학회 2014 정보 및 제어 심포지엄 논문집 Vol.2014 No.4

향정신성약물의 행동학적 독성

윤진상,Yoon, Jin-Sang 대한생물정신의학회 1998 생물정신의학 Vol.5 No.1

Any compound which disrupts the integrity of psychological aspects of performance, in particular, cognitive ability and psychomotor function analogous to the psychological behaviors of routine life, is known to be behaviorally toxic. A significant level of behavioral toxicity will interfere with patient safety and quality of life, and also may be counter-therapeutic by exacerbating the condition that the drug was prescribed for. Now, behavioral toxicity of psychotropic drugs has become one of the main growth areas of psychopharmacological research. Evaluation of the potential of drug-induced behavioral toxicity is important not only to the experimental researcher involved in human psychopharmacology, but also to the clinical practitioner treating psychiatric patients. This article attempts to describe behavioral toxicity of the three classes of psychotropic drugs - benzodiazepines, antidepressants and neuroleptics. After a brief discussion of some methodological issues arising in the investigation of behavioral toxicity, each of these drug classes is reviewed in the context of practical importance rather than purely scientific concern. The last session summarizes some suggestions for future studies on drug-induced behavioral toxicity.

항정신병약물에 의한 부작용의 치료전략

윤진상,신일선,Yoon, Jin-Sang,Shin, Il-Seon 대한생물정신의학회 1998 생물정신의학 Vol.5 No.2

항정신병약물에 의한 부작용의 치료전략은 예방이 최우선이며, 그 다음이 조기발견 및 이에 대한 적절한 치료이다. 항정신병약물의 부작용을 강조하는 이유는, 약물에 대한 부정적 인상을 강화시키려는 데 있지 않고, 약물의 치료적 효과를 극대화시키려는 데 있다. 이를 위해서는 약물의 속성과 환자의 특징을 고려한 약물의 선택과 사용뿐만 아니라, 부작용에 대한 면밀한 이해와 이에 대한 치료전략을 숙지해야 한다. While the therapeutic efficacy of antipsychotic drugs is not in doubt, a variety of undesirable side effects are common. They can be a disincentive to good compliance with treatment, resulting in increased possibilities for relapse and hospitalization. They can be distressing and disabling and thus interfering with patient safety and quality of life. Furthermore, they may be counter-therapeutic by exacerbating the condition that the drug was prescribed for. In this article, we will provide an overview of management of antipsychotic- induced side effects, with a particular emphasis on the most common side effects as well as less common but serious side effects. In addition, some practical issues regarding the management of side effects will be discussed.

정상성인에서 ALDH-I의 변이가 알콜의 정신운동성 수행과 주관적 평가에 미치는 영향

윤보현,윤진상,Yoon, Bo Hyun,Yoon, Jin Sang 대한생물정신의학회 1996 생물정신의학 Vol.3 No.2

The purpose of this study was to evaluate the effects of alcohol on the psychomotor performance and subjective assessment in healthy Korean adults with acetaldehyde dehydrogenase I(ALDH-I) isozyme variance. A total of 20 male subjects, half with active ALDH-I and the other half with inactive ALDH-I, were selected through both a self-reporting questionnaire examining alcohol sensitivity and the Higuchi's ethanol patch test detecting ALDH-I deficiency. In a doule-blind, placebo-controlled cross-over design, each subject consumed four doses of alcohol(0.25, 0.5, 0.75, 1.0g/kg) and placebo on five separate occasions at weekly intervals, Treatment order was fully balanced using a $5{\times}5$ Latin square, Psychomotor performance tests[coritical flicker fusion threshold(CFF) and choice reaction time(CRT)] and self-estimate questionnaires were conducted at baseline and at time points of 20, 40, 60, 90, 120, 150, 180 minutes after consuming the test drug for 20 minutes, Blood alcohol concentrations(BACs) using breath analyzer were measured at baseline and at time points of 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180 minutes after drinking, The BACs and the mean changes in the psychomotor performances and subjective assessments from pre-alcohol baseline, were compared between the two groups. The findings were summarized as follows : 1) BACs were tended to be higher in the inactive group than the active in all of the four alcohol doses. However significant group differences were only after the 0.5g/kg dose of alcohol. 2) The inactive group showed significant impairment in CFFT at most time points alter 0.75 and 1.0g/kg doses of alcohol. 3) In CRT, total reaction time(TRT) significantly prolonged in the inactive group than the active group at 20 minutes after 0.25 and 1.0g/kg doses of alcohol and at 40, 60, 90 minutes alter 0.75g/kg dose of alcohol. In the inactive group, recognition time component significantly increased at 20, 60, 90 minutes after 1.0g/kg dose of alcohol, while movement time component significantly increased at 40, 60 minutes after 0.75g/kg dose of alcohol. 4) Subjective evaluation of the effect of alcohol revealed that physical and mental conditions as well as a self-estimate of the effects of alcohol on performance were significantly worse in the inactive group than the active at some time points alter all of the lour alcohol doses, wihch were more pronounced after 0.75 and 1.0g/kg doses of alcohol. 5) Most of the group differences mentioned above, still remained statistically significant after BAC was entered as a covariate, These findings demonstrated that the alcohol sensitivity is higher in individuals with inactive ALDH-I than those with active ALDH-I both on the subjective assessments and the objective psychomotor performances. Furthermore, these results suggest thai the alcohol sensitivity may be determined by acetaldehyde concentration rather than BAC per se. In future studies, after more accurate genotyping for ALDH-I, the relationships between BAC, acetaldehyde concentration and alcohol sensitivities should be clearly defined. ALDH-I 활성군과 비활성군에서 음주후 정신운동성 수행 및 주관적 평가에 미치는 영향을 비교하였다. 사교적 음주에 상응하는 4종류의 알콜(0.25, 0.5, 0.75, 1.0g/kg)을 투여한 결과 비활성군이 활성군에 비해 보다 부정적인 평가를 하였다. 이는 특히 고용량의 알콜(0.75 및 1.0g/kg)을 투여시 분명하였다. 이러한 결과는 비활성군이 활성군에 비해 알콜에 대한 민감성이 주관적인 판단과 객관적인 수행에서 모두 더 높다는 사실을 반영한다.

2015노년기 신체질환이 불안의 발생에 미치는 전향적 연구

김상대(Sang-Dae Kim),강희주(Hee-Ju Kang),이주연(Ju-Yeon Lee),김선영(Seon-Young Kim),배경열(Kyung-Yeol Bae),김성완(Sung-Wan Kim),김재민(Jae-Min Kim),신일선(Il-Seon Shin),윤진상(Jin-Sang Yoon) 대한생물치료정신의학회 2015 생물치료정신의학 Vol.21 No.3